UroGen Pharma Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021	2020	2019	2018	2017
Market Capitalization	515	463	205	213	398	700	592	484
Market Cap Growth	-	126.06%	-3.94%	-46.44%	-43.13%	18.23%	22.32%	-
Enterprise Value	477	425	203	123	296	555	491	411
PE Ratio	-4.53	-4.53	-1.87	-1.92	-3.10	-6.66	-7.83	-24.20
PS Ratio	6.23	5.60	3.18	4.44	33.74	38893.81	524.94	59.34
PB Ratio	-7.10	-7.10	-2.29	25.34	4.13	3.88	6.57	7.07
P/FCF Ratio	-6.05	-6.05	-2.33	-2.49	-3.72	-9.81	-15.63	-49.20
P/OCF Ratio	-6.06	-6.06	-2.34	-2.51	-3.76	-9.86	-15.86	-50.60
EV/Sales Ratio	5.76	5.13	3.16	2.57	25.12	30838.48	434.90	50.37
EV/EBITDA Ratio	-5.18	-5.18	-2.08	-1.15	-2.41	-5.35	-6.39	-20.81
EV/EBIT Ratio	-5.08	-5.08	-2.04	-1.13	-2.37	-5.28	-6.36	-20.60
EV/FCF Ratio	-5.55	-5.55	-2.31	-1.44	-2.77	-7.78	-12.95	-41.76
Debt / Equity Ratio	-1.52	-1.52	-1.11	0.05	0.02	0.01	-	-
Debt / EBITDA Ratio	-1.21	-1.21	-1.01	0.00	-0.01	-0.03	-	-
Debt / FCF Ratio	-1.30	-1.30	-1.13	0.00	-0.01	-0.04	-	-
Quick Ratio	4.91	4.91	4.74	4.56	5.15	7.58	7.54	10.40
Current Ratio	5.42	5.42	5.39	5.11	5.39	7.63	7.59	10.59
Asset Turnover	0.57	0.57	0.45	0.38	0.08	0	0.01	0.17
Interest Coverage	-5.68	-5.68	-11.80	-	-	-	-	-643.55
Return on Equity (ROE)	112.90%	112.90%	208.50%	-256.70%	-100.80%	-49.20%	-70.20%	-47.20%
Return on Assets (ROA)	-70.50%	-70.50%	-76.20%	-87.70%	-87.10%	-45.70%	-64.80%	-40.60%
Return on Capital (ROIC)	-191.72%	-191.72%	-809.68%	-1047.46%	-129.52%	-59.85%	-85.67%	-29.12%
Earnings Yield	-19.84%	-22.08%	-53.60%	-51.98%	-32.27%	-15.02%	-12.78%	-4.13%
FCF Yield	-14.86%	-16.54%	-42.88%	-40.17%	-26.90%	-10.19%	-6.40%	-2.03%
Buyback Yield / Dilution	-26.43%	-26.43%	-2.06%	-2.60%	-6.10%	-30.31%	-62.13%	-321.46%
Total Shareholder Return	-26.43%	-26.43%	-2.06%	-2.60%	-6.10%	-30.31%	-62.13%	-321.46%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).